Katherine Stueland Sells 10,857 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,857 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $143.89, for a total transaction of $1,562,213.73. Following the completion of the transaction, the chief executive officer directly owned 14,237 shares of the company’s stock, valued at approximately $2,048,561.93. This represents a 43.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Katherine Stueland also recently made the following trade(s):

• On Tuesday, December 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The stock was sold at an average price of $159.28, for a total transaction of $579,619.92.
• On Wednesday, October 29th, Katherine Stueland sold 2,158 shares of GeneDx stock. The stock was sold at an average price of $136.54, for a total transaction of $294,653.32.

GeneDx Stock Up 3.0%

WGS opened at $140.44 on Friday. The business’s fifty day simple moving average is $141.11 and its 200 day simple moving average is $115.97. GeneDx Holdings Corp. has a 52 week low of $55.17 and a 52 week high of $170.87. The company has a quick ratio of 2.59, a current ratio of 2.71 and a debt-to-equity ratio of 0.18. The stock has a market cap of $4.06 billion, a PE ratio of 1,560.44 and a beta of 1.99.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.21. The firm had revenue of $116.74 million during the quarter, compared to analysts’ expectations of $104.33 million. GeneDx had a return on equity of 20.22% and a net margin of 0.52%. As a group, research analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Institutional Trading of GeneDx

Institutional investors have recently modified their holdings of the company. US Bancorp DE increased its holdings in GeneDx by 3,223.5% during the 1st quarter. US Bancorp DE now owns 565 shares of the company’s stock valued at $50,000 after purchasing an additional 548 shares during the period. PNC Financial Services Group Inc. bought a new stake in shares of GeneDx in the 1st quarter worth approximately $132,000. Vanguard Group Inc. increased its stake in shares of GeneDx by 2.5% during the first quarter. Vanguard Group Inc. now owns 1,031,326 shares of the company’s stock valued at $91,339,000 after buying an additional 25,116 shares during the period. Swiss National Bank raised its holdings in shares of GeneDx by 34.0% during the first quarter. Swiss National Bank now owns 31,900 shares of the company’s stock valued at $2,825,000 after acquiring an additional 8,100 shares in the last quarter. Finally, Nuveen LLC bought a new position in shares of GeneDx during the first quarter valued at approximately $17,528,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently commented on WGS. Guggenheim reaffirmed a “buy” rating and set a $170.00 target price (up previously from $115.00) on shares of GeneDx in a report on Wednesday, October 29th. Piper Sandler raised their price objective on GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, September 11th. Wall Street Zen downgraded GeneDx from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Zacks Research cut GeneDx from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 2nd. Finally, BTIG Research raised their price target on GeneDx from $165.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, GeneDx presently has an average rating of “Moderate Buy” and an average target price of $134.78.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.